10 mg vial of tirzepatide UPB Tirz 10MG (Box 10, Double Agonist) Tirzepatide Flex-Dose 1 mL Injectable

Some patients experience mild digestive discomfort during the adjustment period

Continuous monitoring ensures adjustments align with evolving needs, fostering lasting results rather than short-term changes

Patients in Texas appreciate knowing that expert monitoring keeps their progress steady and reliable

[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)

It contains an active ingredient called Tirzepatide, produced by Eli Lilly